entertainment
WASHINGTON — There’s about to be a new acronym in town.
The Food and Drug Administration is in the final stages of cementing sweeping changes to the Office of Regulatory Affairs, which oversees inspections and compliance for all its regulated products, according to three people familiar with the planning.
advertisement
That overhaul includes a new name: Meet the Office of Inspections and Investigations.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
How to make the FDA’s new prescription one
Next article： Drug repurposing or repositioning? The language matters
Next article： Drug repurposing or repositioning? The language matters
